Breaking News Instant updates and real-time market news.

VZ

Verizon

$48.94

-0.28 (-0.57%)

, PM

Philip Morris

$113.91

-1.3 (-1.13%)

20:25
04/19/17
04/19
20:25
04/19/17
20:25

Notable companies reporting before tomorrow's open

Notable companies reporting before tomorrow's open, with earnings consensus, include Verizon (VZ), consensus 97c... Philip Morris (PM), consensus $1.03... Danaher (DHR), consensus 84c... BNY Mellon (BK), consensus 80c... BB&T (BBT), consensus 73c... Travelers (TRV), consensus $2.38... Sherwin-Williams (SHW), consensus $2.05... PPG Industries (PPG), consensus $1.32... KeyCorp (KEY), consensus 28c... Nucor (NUE), consensus $1.07... Citizens Financial (CFG), consensus 51c... Quest Diagnostics (DGX), consensus $1.18... Alliance Data Systems (ADS), consensus $3.86... D.R. Horton (DHI), consensus 59c... Dover (DOV), consensus 61c... Snap-on (SNA), consensus $2.36... People's United Financial (PBCT), consensus 22c.

VZ

Verizon

$48.94

-0.28 (-0.57%)

PM

Philip Morris

$113.91

-1.3 (-1.13%)

DHR

Danaher

$86.44

-0.1 (-0.12%)

BK

BNY Mellon

$46.86

-0.03 (-0.06%)

BBT

BB&T

$42.63

0.06 (0.14%)

TRV

Travelers

$120.40

-0.35 (-0.29%)

SHW

Sherwin-Williams

$311.54

0.47 (0.15%)

PPG

PPG

$105.00

0.26 (0.25%)

KEY

KeyCorp

$17.37

0.17 (0.99%)

NUE

Nucor

$57.62

0.29 (0.51%)

CFG

Citizens Financial

$34.22

0.52 (1.54%)

DGX

Quest Diagnostics

$98.11

1 (1.03%)

ADS

Alliance Data

$240.64

2.64 (1.11%)

DHI

D.R. Horton

$33.95

-0.33 (-0.96%)

DOV

Dover

$79.26

-0.84 (-1.05%)

SNA

Snap-On

$163.77

0.46 (0.28%)

PBCT

People's United

$17.54

0.18 (1.04%)

  • 19

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 24

    Apr

  • 27

    Apr

  • 03

    May

  • 03

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 11

    May

  • 16

    May

  • 17

    May

  • 31

    May

  • 20

    Jul

  • 19

    Oct

VZ Verizon
$48.94

-0.28 (-0.57%)

04/19/17
PACS
04/19/17
NO CHANGE
PACS
Zayo Group has negative read through from Verizon deal, says Pacific Crest
After Verizon (VZ) agreed to buy fiber from Corning (GLW), Pacific Crest analyst Brandon Nispel says the deal indicates that Verizon prefers to build a fiber network on its own instead of leasing one from a third party. The analyst views this development as negative for Zayo which is building and looking to lease fiber networks. He keeps a Sector Weight rating on the stock.
04/19/17
ARGS
04/19/17
NO CHANGE
ARGS
Corning price target raised to $33 from $30 at Argus
Argus analyst Jim Kelleher increased his price target on Corning (GLW) after the company announced a $1.05B fiber supply deal with Verizon (VZ). The analyst says that Corning's valuation is attractive and keeps a Buy rating on the shares.
04/19/17
STFL
04/19/17
NO CHANGE
STFL
Dycom could obtain $300M in revenue from Verizon, says Stifel
After Verizon (VZ) announced a three year agreement to purchase fiber from Corning (GLW), Stifel analyst Noelle Dilts says that Verizon's upcoming deployment of fiber could generate $300M of additional annual revenue for Dycom (DY). The analyst estimates that Verizon's deployment could add 64c to Dycom's annual EPS. She raised her price target on the shares to $120 from $112 and keeps a Buy rating on the stock.
04/19/17
04/19/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. ING Group (ING) initiated with a Buy at Jefferies. 2. T-Mobile (TMUS) was initiated with a Buy at SunTrust while Sprint (S), Verizon (VZ), and AT&T (T) were initiated with a Hold. 3. DXC Technology (DXC) initiated with an Overweight at JPMorgan. 4. LendingClub (LC) coverage resumed with a Hold at Stifel. 5. Halliburton (HAL) and Schlumberger (SLB) were initiated with a Buy at HSBC while Baker Hughes (BHI) was initiated with a Hold. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
PM Philip Morris
$113.91

-1.3 (-1.13%)

01/17/17
WELS
01/17/17
NO CHANGE
WELS
Wells sees Reynolds American deal upping chances of Philip Morris, Altria tie-up
After Reynolds American (RAI) announced that it has reached an agreement with British American Tobacco (BTI) under which BAT will acquire the 57.8% of RAI common stock that BAT does not currently own, Wells Fargo analyst Bonnie Herzog said she sees the deal increasing the likelihood of Philip Morris (PM) acquiring Altria (MO) as scale becomes increasingly critical. Applying the deal multiple for Reynolds' deal, Herzog estimates that Altria is worth at least $76 per share in a potential takeover.
02/17/17
WELS
02/17/17
NO CHANGE
WELS
Philip Morris likely to raise iQOS guidance, says Wells Fargo
Wells Fargo expects Philip Morris (PM) to announce on February 22 that it will file an FDA application to commercialize its iQOS smokeless cigarettes in the U.S. The firm predicts that the company will also raise its 2020 iQOS incremental profit target by $0.3B to $1.0-$1.5B. Wells sees a 70% chance of Philip Morris acquiring Altria Group (MO), and it says that such a deal could enable iQOs to obtain an additional $10B in operating income from iQOS by 2025. Wells keeps Outperform ratings on Philip Morris and Altria.
01/18/17
SBSH
01/18/17
DOWNGRADE
Target $60
SBSH
Neutral
Reynolds American downgraded to Neutral from Buy at Citi
Citi analyst Adam Spielman downgraded Reynolds American (RAI) to Neutral from Buy citing its deal to be acquired fully by British American Tobacco (BTI). He adds that he sees the proposed deal putting further pressure on Altria (MO) and Philip Morris (PM) to recombine.
02/08/17
SBSH
02/08/17
NO CHANGE
SBSH
Citi says 'fairly unlikely' Philip Morris buys Altria Group
It is "fairly unlikely," although not impossible, that Philip Morris (PM) acquires Altria Group (MO), Citi analyst Adam Spielman tells investors in a research note. The analyst points out that according to Bloomberg, there is greater speculation that Altria Group will be bid for than for any other major company. Spielman does not believe Philip Morris buying Altria would generate adequate financial returns. He notes the takeover speculation is triggered by British American Tobacco's (BAT) decision to buy Reynolds American (RAI), the number two player in U.S. tobacco.
DHR Danaher
$86.44

-0.1 (-0.12%)

02/24/17
SBSH
02/24/17
UPGRADE
Target $98
SBSH
Buy
Danaher upgraded to Buy from Neutral at Citi
Citi analyst Andrew Kaplowitz upgraded Danaher to Buy and raised his price target for the shares to $98 from $86.
02/01/17
FBCO
02/01/17
UPGRADE
FBCO
Outperform
Danaher upgraded to Outperform from Neutral at Credit Suisse
02/01/17
02/01/17
UPGRADE
Target $93

Outperform
Danaher upgraded to Outperform at Credit Suisse
As previously reported, Credit Suisse analyst Erin Wilson Wright upgraded Danaher to Outperform from Neutral after assuming coverage of the stock on enthusiasm for its growing exposure to compelling recurring revenues streams, healthy innovation pipeline, significant room for margin improvement, and capital deployment optionality. The analyst also raised her price target on the shares to $93 from $80.
02/01/17
02/01/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: Amgen (AMGN) upgraded to Buy from Neutral at BofA/Merrill with analyst Ying Huang saying he expects 14% earnings growth in 2017, compared to consensus of 8% and 8% for major pharma peers. Like consensus, Huang expects a downward trend for Epogen, but said the recent Davita (DVA) contract should result in a more gradual decline and the delay in Neulasta biosimilar launch will also help stabilize Amgen's revenue. Additionally, the analyst expects a positive outcome for the highly anticipated Repatha's cardiovascular outcome trial, new product launches in 2017, and potential benefits from cash repatriation. 2. Coach (COH) upgraded to Buy from Hold at Evercore ISI with analyst Omar Saad saying there are increasing signs that Coach is being successful in translating its full-price store formula to its lagging outlet business as it has undergone an ambitious brand turnaround over the past few years. 3. Leggett & Platt (LEG) upgraded to Strong Buy from Market Perform at Raymond James with analyst Budd Bugatch changing his view following the fourth quarter report and conference call saying he expects new bedding introductions to gain traction with a variety of mattress makers, spurring incremental 2017 growth, its vertical integration and market share position provide pricing power, and shares have declined 9% from its peak over the last six months. 4. Danaher (DHR) upgraded to Outperform from Neutral at Credit Suisse with analyst Erin Wilson Wright assuming coverage of the stock on enthusiasm for its growing exposure to compelling recurring revenues streams, healthy innovation pipeline, significant room for margin improvement, and capital deployment optionality. The analyst also raised her price target on the shares to $93 from $80. 5. Constellation Brands (STZ) upgraded to Hold from Reduce at HSBC with analyst Carlos Laboy citing the stock's 15% correction since the three-month high. The analyst views the stock as fairly valued and raised his price target for the shares to $153 from $132. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BK BNY Mellon
$46.86

-0.03 (-0.06%)

01/19/17
KBWI
01/19/17
DOWNGRADE
Target $48
KBWI
Market Perform
BNY Mellon downgraded to Market Perform from Outperform at Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl downgraded BNY Mellon to Market Perform citing lower expectations after the company's Q4 results missed his estimates. The analyst lowered his price target for the shares to $48 from $54.
03/03/17
EVER
03/03/17
DOWNGRADE
Target $48
EVER
Underperform
BNY Mellon downgraded to Underperform from Hold at Evercore ISI
Evercore ISI changed its rating system to Outperform, In Line and Underperform. Analyst Glenn Schorr downgraded BNY Mellon saying shares will benefit less versus peers from lower taxes, higher loan growth better capital markets, and financial deregulation. Schorr expects Trust Banks to have ongoing fee compression in core custody, lower NIR rate leverage, and increased competition. Schorr maintained his $48.50 price target on BNY Mellon shares.
04/13/17
DBAB
04/13/17
NO CHANGE
DBAB
Deutsche recommends long BNY Mellon, short State Street pair trade
Ahead of earnings reports from the brokers, asset managers and exchanges, Deutsche Bank analyst Brian Bedell recommends a pair trade to go long BNY Mellon (BK) versus short State Street (STT), as he sees NY Mellon narrowly beating consensus while he expects State Street to post a slight miss and also predicts downward revisions to 2017. Bedell keeps a Buy rating on BNY Mellon and a Hold rating on State Street.
01/20/17
01/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) downgraded to Market Perform from Outperform at Cowen with analyst Steve citing the company's announcement that it is not pursuing an early regulatory filing of the Opdivo plus Yervoy combination in first-line treatment of non-small cell lung cancer. He cut his price target on Bristol shares to $65 from $85. 2. BNY Mellon (BK) downgraded to Market Perform from Outperform at Keefe Bruyette with analyst Brian Kleinhanzl citing lower expectations after the company's fourth quarter results missed his estimates. The analyst lowered his price target for the shares to $48 from $54. 3. Western Union (WU) downgraded to Sell from Neutral at Compass Point. 4. Teva (TEVA) downgraded to Neutral from Overweight at JPMorgan with analyst Chris Schott saying the generic operating environment remains challenging. 5. CSX (CSX) downgraded to Hold from Buy at Deutsche Bank with analyst Amit Mehrotra citing valuation following yesterday's 23% rally. The stock is within 5% of the analyst's "Blue Sky" scenario and above his unchanged price target of $42. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BBT BB&T
$42.63

0.06 (0.14%)

03/06/17
HDLY
03/06/17
DOWNGRADE
HDLY
Neutral
BB&T downgraded to Neutral from Buy at Hilliard Lyons
Hilliard Lyons analyst Andrew Stapp downgraded BB&T with a $51 price target due to valuation. The analyst now expects FED hikes in 2017 to be earlier than perceived and is now modeling rate hikes in March and September versus June and December previously.
12/20/16
HDLY
12/20/16
DOWNGRADE
HDLY
Neutral
BB&T downgraded to Neutral from Buy at Hilliard Lyons
01/11/17
UBSW
01/11/17
INITIATION
Target $49
UBSW
Neutral
BB&T initiated with a Neutral at UBS
UBS analyst Saul Martinez started BB&T with a Neutral rating and $49 price target.
01/23/17
HDLY
01/23/17
UPGRADE
HDLY
Buy
BB&T upgraded to Buy from Neutral at Hilliard Lyons
TRV Travelers
$120.40

-0.35 (-0.29%)

02/13/17
FBRC
02/13/17
DOWNGRADE
Target $119
FBRC
Market Perform
Travelers downgraded to Market Perform from Outperform at FBR Capital
FBR Capital analyst Randy Binner downgraded Travelers to Market Perform citing valuation and pricing challenges in the auto segment and broader commercial lines. The analyst has a $119 price target for the shares.
01/17/17
MACQ
01/17/17
UPGRADE
MACQ
Outperform
Travelers upgraded to Outperform from Underperform at Macquarie
Macquarie analyst Amit Kumar upgraded Travelers two notches to Outperform from Underperform with a $134 price target. The analyst expects Travelers to significantly benefit from the improving US business environment due to Trump's focus on business and a lower corporate tax rate.
01/10/17
GSCO
01/10/17
DOWNGRADE
Target $107
GSCO
Sell
Travelers downgraded to Sell from Neutral at Goldman
Goldman analyst Michael Nannizzi downgraded Travelers to Sell and lowered its price target to $107 from $116. The analyst said shares are up 10% since the election and sees fewer catalysts ahead given its large muni portfolio and lack of rate action to date.
01/26/17
JPMS
01/26/17
NO CHANGE
Target $120
JPMS
Neutral
JPMorgan incrementally cautious after Travelers meeting
JPMorgan analyst Sarah DeWitt says she's incrementally cautious on shares of Travelers after meeting with the company's management. The analyst says she didn't receive "significant comfort" that auto insurance losses won't deteriorate further while higher U.S. inflation could mean reserve releases slow. The analyst adds that management "appeared slightly less inclined" to pursue acquisitions. DeWitt keeps a Neutral rating on Travelers with a $120 price target.
SHW Sherwin-Williams
$311.54

0.47 (0.15%)

02/01/17
SUSQ
02/01/17
NO CHANGE
Target $350
SUSQ
Positive
Sherwin-Williams price target raised to $350 from $330 at Susquehanna
Susquehanna analyst Don Carson raised his price target on Sherwin-Williams to $350 from $330 following Q4 results. The analyst cited the abatement of the labor constraints that negatively impacted Q3 results and the expectation the company will grow U.S. architectural volumes at twice the market rate. Carson reiterated his Positive rating on Sherwin-Williams shares.
02/07/17
MSCO
02/07/17
NO CHANGE
Target $335
MSCO
Overweight
Sherwin-Williams price target raised to $335 from $300 at Morgan Stanley
Morgan Stanley analyst Vincent Andrews raised Sherwin-Williams price target to $335 and reiterated his Overweight rating. Andrews is more positive on the US housing market than either global auto OEM or other OEM and industrial end markets and believes the company has the ability to prices in excess inflation faster.
04/03/17
KEYB
04/03/17
UPGRADE
Target $375
KEYB
Overweight
Sherwin-Williams upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Michael Sison upgraded Sherwin-Williams to Overweight saying the Valspar acquisition, which should close in Q2, will provide "consistent" earnings growth and margin expansion through the 2019. The analyst has a $375 price target for the shares.
04/18/17
MSCO
04/18/17
NO CHANGE
MSCO
Contractor survey indicates strength in home improvement, says Morgan Stanley
Morgan Stanley analysts led by Vincent Andrews said the firm's recent contractor survey indicates strong home improvement trends over the last 3 months and points to an optimistic outlook ahead for the Spring season. The analyst said results support a constructive view for Home Depot (HD), Lowe's (LOW), and Sherwin-Williams (SHW).
PPG PPG
$105.00

0.26 (0.25%)

03/09/17
BARD
03/09/17
NO CHANGE
BARD
PPG negotiations with AkzoNobel likely ongoing, says Baird
Baird said PPG's (PPG) negotiations with AkzoNobel (AKZOY) are likely ongoing despite Akzo's rejection. The firm's analyst believes potential anti-trust issues and fluid negotiation between the companies will likely result in an elongated timeline for any deal to close.
03/23/17
RBCM
03/23/17
NO CHANGE
RBCM
AkzoNobel could be acquired for EUR100 per share, says RBC Capital
After PPG (PPG) made a second, EUR 88 per share bid for Akzo Nobel (AKZOY) and the bid was rejected, RBC Capital analyst Arun Viswanathan says that a hypothetical EUR 100 per share bid is "a fair value and one Akzo might be more willing to accept." The analyst says that such a deal would be accretive for PPG if it was done in all cash.
03/15/17
ATLE
03/15/17
UPGRADE
Target $125
ATLE
Overweight
PPG upgraded to Overweight from Neutral at Atlantic Equities
Atlantic Equities analyst Colin Isaac upgraded PPG to Overweight and raised his price target for the shares to $125 from $110.
03/10/17
RHCO
03/10/17
NO CHANGE
RHCO
PPG likely to continue pursuit of AkzoNobel, says SunTrust
After AkzoNobel,(AKZOY) rejected a bid by PPG (PPG), SunTrust analyst James Sheehan says he expects PPG to continue pursuing the deal, given what he sees as the "strong strategic rationale" for the transaction. He says that PPG's valuation is attractive and he keeps a Buy rating on the stock.
KEY KeyCorp
$17.37

0.17 (0.99%)

03/03/17
03/03/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Expedia (EXPE) upgraded to Neutral from Sell at Citi with analyst Mark May citing greater comfort in the growth of the company's hotel business. The analyst, who noted that recently disclosed room night and bookings growth at HomeAway gives him a more bullish view on its long-term growth, raised his price target on Expedia shares to $130 from $116. 2. Helmerich & Payne (HP) upgraded to Outperform from Market Perform at Bernstein with analyst Colin Davies citing higher U.S. rig demand and valuation. Target to $84 from $86. 3. Dr Pepper Snapple (DPS) upgraded to Buy from Hold at Jefferies with analyst Kevin Grundy saying that its recently-acquired Bai brand is an underappreciated growth platform for the company. He expects Bai to contribute 2-3 points to Dr Pepper's core sales growth over the next 3-5 years and increased his 2017-18 organic sales and EPS forecasts. Grundy increased his price target on Dr Pepper shares to $115 from $98. 4. KeyCorp (KEY) upgraded to Outperform from Hold at Evercore ISI. 5. Southern Company (SO) upgraded to Buy from Hold at Jefferies with analyst Anthony Crowdell saying he thinks the company will be able to deliver on its 5% earnings per share growth target given all the levers available to pull. He also believes investors are pricing in a Kemper scenario that is worse than worst-case and sees the Vogtle nuclear project is less of a concern than is factored in at current levels, Crowdell tells investors. He raised his price target on Southern Company shares to $56 from $50. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/03/17
EVER
03/03/17
UPGRADE
EVER
Outperform
KeyCorp upgraded to Outperform from Hold at Evercore ISI
03/23/17
DADA
03/23/17
INITIATION
Target $19
DADA
Neutral
KeyCorp initiated with a Neutral at DA Davidson
DA Davidson analyst Kevin Reevey initiated KeyCorp with a Neutral and a $19 price target saying above-peer delinquencies and net charge-offs in its auto loan portfolio could limit near-term multiple expansion.
01/20/17
SDLR
01/20/17
DOWNGRADE
SDLR
Hold
KeyCorp downgraded to Hold from Buy at Sandler O'Neill
NUE Nucor
$57.62

0.29 (0.51%)

02/13/17
02/13/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. J.C. Penney (JCP) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Kimberly Greenberger saying valuation appears more balanced following a 14% decline year-to-date and potential catalysts ahead. 2. Regeneron (REGN) upgraded to Overweight from Neutral at Piper Jaffray with analyst Edward Tenthoff saying that while Eylea growth is slowing, new approvals are coming. The analyst expects Dupixent approval in atopic dermatitis by the March 29 FDA action date and Phase III Liberty Asthma Quest data and potential supplemental Biologics License Application by year-end. 3. Petrobras (PBR) upgraded to Overweight from Neutral at JPMorgan with analyst Rodolfo Angele saying the shares are back to September 2016 levels despite "many positive" developments since then. 4. Nucor (NUE) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Evan Kurtz saying Nucor has more favorable risk/reward than AK Steel (AKS), which was downgraded to Equal Weight, given its low cost profile, margin stability, attractive end market mix, and potential benefits from favorable rulings on ongoing rebar and plate trade cases. 5. Allscripts (MDRX) upgraded to Buy from Neutral at Dougherty with analyst Gene Mannheimer citing a strong 2017 outlook partly due to Sunrise expansion, checks that indicate traction in the Allscripts open platform, and opportunities for growth from the NetSmart joint venture. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/22/17
JPMS
03/22/17
NO CHANGE
Target $46
JPMS
Overweight
JPMorgan ups targets in steel, U.S. Steel remains top pick
JPMorgan analyst Michael Gambardella raised his estimates and price targets for U.S. Steel (X), Steel Dynamics (STLD), Nucor (NUE) and AK Steel (AKS) citing conviction that the companies are "poised for stronger earnings growth over the next several quarters." Steel sheet imports will trend downward, even if the Trump administration just enforces existing trade laws, Gambardella tells investors in a research note. U.S. Steel remains his top pick in Metals & Mining. Gambardella raised his price target for the shares to $46 from $39. The analyst also raised his price target for Overweight-rated Nucor to $75 from $70 and Overweight-rated Steel Dynamics to $44 from $41. His target on Neutral-rated AK Steel moved up to $9 from $8.
03/27/17
MSCO
03/27/17
NO CHANGE
MSCO
Steel cost deflatoin could lead to a near-term price peak, says Morgan Stanley
Morgan Stanley analyst Evan Kurtz said East Coast export scrap prices have fallen $30/ton, which could negatively influence April scrap price settlements. The analyst said with no clear change in supply-demand dynamics, coast deflation could lead to a near-term price peak. Kurtz would view any weakness in the space as an opportunity to buy top picks Nucor (NUE), Steel Dynamics (STLD), and U.S. Steel (X).
03/29/17
COWN
03/29/17
NO CHANGE
COWN
Steel sentiment has deteriorated, may have further downside, says Cowen
Cowen analyst Novid Rassouli sand the sentiment in steel stocks has deteriorated following the drop in oil prices, the non-repeal of ACA, and tightening Chinese credit. Rassouli said US HRC prices may come under near-term pressure due to widening domestic versus international spreads and failing scrap prices, leading to additional downside in steel names. The analyst said U.S. Steel (X) and AK Steel (AKS) are the most levered to HRC prices, ArcelorMittal (MT) could see additional downside if iron ore prices continue lower, and views Steel Dynamics (STLD) and Nucor (NUE) as defensive plays given lower fixed cost structures.
CFG Citizens Financial
$34.22

0.52 (1.54%)

01/23/17
RAFF
01/23/17
UPGRADE
RAFF
Buy
Citizens Financial upgraded to Buy from Hold at Rafferty Capital
11/29/16
KBWI
11/29/16
UPGRADE
Target $36
KBWI
Outperform
Citizens Financial upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Brian Klock upgraded Citizens Financial to Outperform to reflect his shift towards banks that have the best positioning in a rising rate environment. The analyst raised his price target for the shares to $36 from $27.
03/29/17
KBWI
03/29/17
NO CHANGE
KBWI
Citizens Financial shares oversold on WSJ article, says Keefe Bruyette
03/30/17
WELS
03/30/17
NO CHANGE
WELS
Citizens Financial weakness overdone, says Wells Fargo
After allegations of improper retail banking sales practices were leveled against Citizens Financial, Wells Fargo says that none of the alleged activities would have increased the bank's revenue or EPS, while it "has been improving branch review/anti-fraud policies for several months." As a result, Wells thinks that the risk of a negative regulatory response" to the matter is relatively low. The firm says that the decline in the company's stock was overdone, and it keeps an Outperform rating on the shares.
DGX Quest Diagnostics
$98.11

1 (1.03%)

03/14/17
GSCO
03/14/17
UPGRADE
Target $113
GSCO
Conviction Buy
Quest Diagnostics upgraded to Conviction Buy from Buy at Goldman
Goldman Sachs analyst Isaac Ro upgraded Quest Diagnostics to Conviction Buy and raised his six-month price target for the shares to $113 from $101. The company should be a key beneficiary as the U.S. healthcare system shifts the cost burden to the individual and creates price transparency for the first time, Ro tells investors in a research note. He believes Quest's ability to gain market share is not factored into consensus estimates.
03/14/17
03/14/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Buy from Neutral at Guggenheim with analyst Michael Morris upgraded saying that he still sees strong potential upside despite the stock's move off its lows as the company enters another expansion cycle for its film, consumer products and parks businesses. The analyst is more cautious on the Networks business, both for Disney and the broader industry, but thinks that is reflected already in Disney shares. Morris raised his price target on Disney shares to $128 from $118. 2. Dick's Sporting (DKS) upgraded to Outperform from Peer Perform at Wolfe Research. 3. Quest Diagnostics (DGX) upgraded to Conviction Buy from Buy at Goldman with analyst Isaac Ro saying the company should be a key beneficiary as the U.S. healthcare system shifts the cost burden to the individual and creates price transparency for the first time. 4. Olympic Steel (ZEUS) and Reliance Steel (RS) were upgraded to Outperform from Neutral at Macquarie, while Worthington (WOR) was upgraded to Neutral from Underperform. 5. Ethan Allen (ETH) upgraded to Strong Buy from Market Perform at Raymond James with analyst Budd Bugatch double upgrading the company saying sales comparisons get easier through 2017 while the retailer's remerchandising effort is behind it, thereby lowering the clearance markdowns. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/16/17
BOFA
03/16/17
UPGRADE
BOFA
Neutral
Quest Diagnostics upgraded to Neutral from Underperform at BofA/Merrill
03/16/17
03/16/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Oracle (ORCL) was upgraded to Market Perform from Underperform at JMP Securities and to Overweight from Neutral at JPMorgan. 2. GoPro (GPRO) upgraded to Neutral from Sell at Citi with analyst Stanley Kovler saying the recent stabilization in revenue as well as the company's "significant" restructuring initiatives accelerate its path to profitability to 2017 from 2019. These developments should, at the very least, stave off the bear scenario for a few quarters, Kovler tells investors in a research note. He raised his price target for GoPro shares to $9 from $8. 2. TJX (TJX) upgraded to Conviction Buy from Buy at Goldman with analyst Matthew Fassler saying the company offers long-term secular growth along with near-term catalysts. The analyst expects TJX to grow market share at the expense of department stores. 4. Inovio (INO) upgraded to Buy from Hold at Maxim with analyst Jason McCarthy saying it has multiple earlier stage programs moving forward with more significant data points coming in 2017 while it moves closer to its pivotal study in cervical dysplasia. He notes that his model assumes that VGX-3100 is commercialized in 2021 for cervical dysplasia. 5. Quest Diagnostics (DGX) upgraded to Neutral from Underperform at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ADS Alliance Data
$240.64

2.64 (1.11%)

03/24/17
DBAB
03/24/17
NO CHANGE
Target $278
DBAB
Buy
Alliance Data price target raised to $278 from $263 at Deutsche Bank
Deutsche Bank analyst Ashish Sabadra raised his price target for Alliance Data Systems to $278 saying higher interest rates and the accelerated share repurchase in early 2017 could potentially drive upside to the full year guidance. The analyst ADS to post an in-line quarter and reiterate its outlook for the year. He keeps a Buy rating on the shares.
04/11/17
OPCO
04/11/17
INITIATION
Target $185
OPCO
Underperform
Alliance Data initiated with an Underperform at Oppenheimer
Oppenheimer analyst Ben Chittenden started Alliance Data with an Underperform rating and a $185 price target, noting that profitability is under pressure and earnings will continue to be driven by the card business.
12/09/16
JPMS
12/09/16
DOWNGRADE
Target $255
JPMS
Neutral
Alliance Data downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Reginald Smith downgraded Alliance Data to Neutral saying higher funding costs and concerns over a peaking consumer credit cycle will weigh on the shares. The analyst lowered his price target for the stock to $255 from $260.
01/26/17
RAJA
01/26/17
DOWNGRADE
RAJA
Market Perform
Alliance Data downgraded to Market Perform from Outperform at Raymond James
DHI D.R. Horton
$33.95

-0.33 (-0.96%)

12/13/16
KBWI
12/13/16
UPGRADE
Target $34
KBWI
Outperform
D.R. Horton upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Jade Rahmani upgraded D.R. Horton to Outperform with an increased price target of $34.
03/07/17
LEHM
03/07/17
NO CHANGE
LEHM
Barclays sees additiona near-term upside for builders
Barclays analyst Michael Dahl says his firm's February survey indicates "strong" early spring demand for U.S. homebuilders. Upcoming catalysts for the group will likely be positive, Dahl tells investors in a research note. The analyst sees "modest" further near-term upside for builder stocks despite the recent rallies. His Overweight rated names are PulteGroup (PHM), Lennar (LEN) and TRI Pointe (TPH). Dahl also believes D.R. Horton (DHI) is well positioned to capture incremental demand. He raised his price target for the shares to $34 from $30 but keeps an Equal Weight rating due to valuation.
02/07/17
BTIG
02/07/17
INITIATION
Target $38
BTIG
Buy
D.R. Horton initiated with a Buy at BTIG
BTIG analyst Carl Reichardt initiated D.R. Horton with a Buy and a $38 price target.
01/05/17
LEHM
01/05/17
INITIATION
Target $28
LEHM
Equal Weight
D.R. Horton initiated with an Equal Weight at Barclays
Barclays analysts Michael Dahl initiated D.R. Horton with an Equal Weight and a $28 price target.
DOV Dover
$79.26

-0.84 (-1.05%)

01/06/17
UBSW
01/06/17
UPGRADE
Target $90
UBSW
Buy
Dover upgraded to Buy from Sell at UBS
UBS analyst Shannon O'Callaghan double upgraded Dover to Buy from Sell saying the company's Energy business should see a "sharp recovery" in 2017-2018 as U.S. rig counts rise and margins improve. The analyst believes current estimates for Dover Energy could prove conservative. O'Callaghan upped the stock's price target to $90 from $65.
04/03/17
04/03/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. BlackBerry (BBRY) upgraded to Outperform from Neutral at Macquarie with the firm's analyst believing fiscal 2018 Street consensus estimates are achievable and expects RADAR to be a material contributor this year. 2. FMC Corporation (FMC) was upgraded to Buy from Hold at SunTrust and to Positive from Neutral at Susquehanna. 3. Dover (DOV) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Nigel Doe citing the sharper recovery in energy spending. 4. AMC Entertainment (AMC) upgraded to Outperform from Market Perform at FBR Capital with analyst Barton Crockett saying he is constructive on the recently completed Nordic acquisition. 5. HCP (HCP) upgraded to Buy from Neutral at BofA/Merrill with analyst Juan Sanabria saying he is positive on HCP's high quality private pay portfolio which stands out in an uncertain regulatory environment and likes its high quality medical office and life science portfolios, which are steady with lower risk assets within healthcare. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/03/17
MSCO
04/03/17
UPGRADE
MSCO
Overweight
Dover upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Nigel Doe upgraded Dover to Overweight with a $90 price target due to the sharper recovery in energy spending. The analyst told investors the Tokheim and Wayne recent acquisitions position the company as a strong top-2 player in the growing, and stable, retail gas equipment market, refrigeration profitability may have bottomed and margins are on a path to recovery in 2017, and Engineered Systems segment growth should accelerate with US IP aided by increased capex.
02/22/17
BMOC
02/22/17
INITIATION
Target $82
BMOC
Market Perform
Dover initiated with a Market Perform at BMO Capital
BMO Capital analyst Scott Graham initiated Dover with a Market Perform and an $82 price target.
SNA Snap-On
$163.77

0.46 (0.28%)

01/09/17
LBOW
01/09/17
NO CHANGE
LBOW
Snap-On, Whirlpool, Brunswick named top picks at Longbow
Longbow analyst David MacGregor named Snap-On (SNA), Whirlpool (WHR), and Brunswick (BC) as his top long picks for 2017. The analyst expects all three companies to continue gaining market share this year, and he predicts that they will all benefit from the Trump Administration's policies.
01/30/17
BARD
01/30/17
NO CHANGE
Target $210
BARD
Outperform
Snap-On price target raised to $210 from $190 at Baird
Baird analyst David Leiker raised his price target to $210 from $190 on Snap-On shares and said he would be an aggressive buyer ahead of its 2017 growth acceleration. The analyst said end markets appear to have accelerated during Q4 and will likely remain tailwinds through 2017. Leiker reiterated his Outperform rating on Snap-On shares.
04/11/17
OPCO
04/11/17
INITIATION
Target $200
OPCO
Outperform
Snap-On initiated with an Outperform at Oppenheimer
Target $200.
12/05/16
LBOW
12/05/16
NO CHANGE
LBOW
Snap-On results poised to beat expectations, says Longbow
After Longbow conducted a survey of Snap-On franchisees, Longbow analyst David MacGregor says that the company's quarterly results are poised to beat expectations. The analyst keeps a $178 price target and a Buy rating on the shares.
PBCT People's United
$17.54

0.18 (1.04%)

12/21/16
SPHN
12/21/16
INITIATION
SPHN
Equal Weight
People's United initiated with an Equal Weight at Stephens
01/05/17
JPMS
01/05/17
INITIATION
Target $20.5
JPMS
Neutral
People's United reinstated with a Neutral at JPMorgan
JPMorgan analyst Steven Alexopoulos reinstated People's United Financial with a Neutral rating and $20.50 price target.
01/06/17
WELS
01/06/17
INITIATION
WELS
Market Perform
People's United initiated with a Market Perform at Wells Fargo
Wells Fargo analyst Jared Shaw started People's United Financial with a Market Perform rating and $17-$18 price target range.
03/10/17
SDLR
03/10/17
UPGRADE
SDLR
Hold
People's United upgraded to Hold from Sell at Sandler O'Neill
Sandler O'Neill upgraded People's United to Hold with a $19.50 price target saying its asset sensitivity position should do well in a higher rate environment.

TODAY'S FREE FLY STORIES

$NYE

NYSE Market Internals

16:16
09/20/17
09/20
16:16
09/20/17
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JUNO

Juno Therapeutics

$45.21

1.41 (3.22%)

16:16
09/20/17
09/20
16:16
09/20/17
16:16
Syndicate
Juno Therapeutics files $225M automatic stock shelf »

Morgan Stanley and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$156.07

-2.66 (-1.68%)

, BSTI

Best Inc.

16:16
09/20/17
09/20
16:16
09/20/17
16:16
General news
On The Fly: Top stock stories for Wednesday »

Stocks were largely on…

AAPL

Apple

$156.07

-2.66 (-1.68%)

BSTI

Best Inc.

BABA

Alibaba

$177.95

-2.12 (-1.18%)

FDX

FedEx

$220.53

4.531 (2.10%)

ADBE

Adobe

$149.96

-6.64 (-4.24%)

GIS

General Mills

$52.17

-3.215 (-5.81%)

CPRT

Copart

$33.86

1.32 (4.06%)

ALNY

Alnylam

$113.78

38.7408 (51.63%)

IONS

Ionis Pharmaceuticals

$53.88

-5.19 (-8.79%)

BBBY

Bed Bath & Beyond

$22.74

-4.29 (-15.87%)

DESP

Despegar.com

CELC

Celcuity

$14.29

14.289 (1,428,900.00%)

ZLAB

Zai Lab

KRYS

Krystal Biotech

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 22

    Oct

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

APC

Anadarko

$44.78

1.02 (2.33%)

16:15
09/20/17
09/20
16:15
09/20/17
16:15
Hot Stocks
Anadarko reaffirms production guidance »

"Separately, we want…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

FCPT

Four Corners Property Trust

$25.32

0.02 (0.08%)

16:14
09/20/17
09/20
16:14
09/20/17
16:14
Hot Stocks
Four Corners Property Trust acquires 41 restaurant properties »

Four Corners Property…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$44.79

1.03 (2.35%)

16:13
09/20/17
09/20
16:13
09/20/17
16:13
Hot Stocks
Anadarko targets $1B of of share repurchases prior to year-end 2017 »

Speaking about the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

TBPH

Theravance Biopharma

$33.07

0.49 (1.50%)

, GSK

GlaxoSmithKline

$40.17

0.25 (0.63%)

16:12
09/20/17
09/20
16:12
09/20/17
16:12
Hot Stocks
GlaxoSmithKline and Innoviva report positive Phase 3 results of Treleg Ellipta »

Theravance Biopharma…

TBPH

Theravance Biopharma

$33.07

0.49 (1.50%)

GSK

GlaxoSmithKline

$40.17

0.25 (0.63%)

INVA

Innoviva

$13.59

0.08 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 24

    Oct

APC

Anadarko

$44.79

1.025 (2.34%)

16:11
09/20/17
09/20
16:11
09/20/17
16:11
Hot Stocks
Anadarko announces $2.5B share repurchase program »

Anadarko Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

QUAD

Quad/Graphics

$20.16

0.33 (1.66%)

16:11
09/20/17
09/20
16:11
09/20/17
16:11
Hot Stocks
Quad/Graphics awarded $450M contract to print all Bluestem catalogs »

Quad/Graphics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

MLHR

Herman Miller

16:11
09/20/17
09/20
16:11
09/20/17
16:11
Hot Stocks
Breaking Hot Stocks news story on Herman Miller »

Herman Miller reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

STBZ

State Bank Financial

$27.79

0.45 (1.65%)

16:08
09/20/17
09/20
16:08
09/20/17
16:08
Hot Stocks
FDIC approves State Bank Financial, AloStar merger transaction »

State Bank Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

16:07
09/20/17
09/20
16:07
09/20/17
16:07
Hot Stocks
Herman Miller CEO says 'encouraged by the strong level of demand' »

Brian Walker, CEO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

ARCC

Ares Capital

$15.85

0.035 (0.22%)

16:07
09/20/17
09/20
16:07
09/20/17
16:07
Initiation
Ares Capital initiated  »

Ares Capital initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

16:06
09/20/17
09/20
16:06
09/20/17
16:06
Earnings
Herman Miller sees Q2 EPS 55c-61c, consensus 56c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

MLHR

Herman Miller

16:05
09/20/17
09/20
16:05
09/20/17
16:05
Earnings
Herman Miller reports Q1 adjusted EPS 57c, consensus 57c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

MDXG

MiMedx

$12.34

-0.82 (-6.23%)

16:05
09/20/17
09/20
16:05
09/20/17
16:05
Hot Stocks
MiMedx responds to two "deceptive short seller articles" »

MiMedx Group responded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

LUNA

Luna Innovations

$1.64

0.05 (3.14%)

16:05
09/20/17
09/20
16:05
09/20/17
16:05
Hot Stocks
Luna Innovations announces stock repurchase program »

Luna Innovations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AERI

Aerie Pharmaceuticals

$53.40

-5.2 (-8.87%)

16:03
09/20/17
09/20
16:03
09/20/17
16:03
Hot Stocks
Aerie announces FDA Advisory Committee meeting for Rhopressa 0.02% »

Aerie Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 28

    Feb

AMD

AMD

$13.12

0.04 (0.31%)

, TSLA

Tesla

$375.10

-9.9 (-2.57%)

15:57
09/20/17
09/20
15:57
09/20/17
15:57
Periodicals
Tesla working with AMD on self-driving car AI chip, CNBC says »

Tesla (TSLA) is using AMD…

AMD

AMD

$13.12

0.04 (0.31%)

TSLA

Tesla

$375.10

-9.9 (-2.57%)

NVDA

Nvidia

$187.35

-0.2 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AMD

AMD

$13.12

0.04 (0.31%)

, TSLA

Tesla

$375.10

-9.9 (-2.57%)

15:54
09/20/17
09/20
15:54
09/20/17
15:54
Periodicals
Breaking Periodicals news story on AMD, Tesla »

Tesla working with AMD on…

AMD

AMD

$13.12

0.04 (0.31%)

TSLA

Tesla

$375.10

-9.9 (-2.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

15:50
09/20/17
09/20
15:50
09/20/17
15:50
General news
More from Yellen: »

More from Yellen: FOMC…

VIX

Volatility Index S&P 500 Options

15:40
09/20/17
09/20
15:40
09/20/17
15:40
Options
Active trading in VIX calls as players replace expiring positions »

Active trading in VIX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:35
09/20/17
09/20
15:35
09/20/17
15:35
General news
Yellen on the FRB »

Yellen on the FRB: she is…

DMPI

DelMar Pharmaceuticals

$1.12

0.0294 (2.70%)

15:33
09/20/17
09/20
15:33
09/20/17
15:33
Syndicate
DelMar Pharmaceuticals announces $10M registered direct offering at-the-market »

DelMar Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$47.94

0.27 (0.57%)

15:30
09/20/17
09/20
15:30
09/20/17
15:30
Options
Far downside put buying in Morgan Stanley »

Far downside put buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 02

    Oct

  • 22

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.